← Human Trials & Peer-Reviewed Studies
Nicotinamide suppresses hyperphosphatemia in hemodialysis patients
Plain-language guide to PMID 14871431 (2004): clinical trial study of NAD+, hyperparathyroidism.
Key Facts
- PMID
- 14871431
- Journal
- Kidney international
- Year
- 2004
- Study type
- Clinical Trial
- Authors
- Takahashi Y et al. (8 authors)
- DOI
- 10.1111/j.1523-1755.2004.00482.x
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at NAD+ in the context of hyperparathyroidism.
The use of calcium- or aluminum-based phosphate binders against hyperphosphatemia is limited by the adverse effects of hypercalcemia or aluminum toxicity in long-term hemodialysis.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
A 2-week posttreatment washout period followed the cessation of nicotinamide.
Blood samples were collected every week for measurement of serum calcium, phosphorus, lipids, iPTH, and blood nicotinamide adenine dinucleotide (NAD).
How the Study Was Run
A time span of 12 weeks appears in the methods.
Nicotinamide was administered for 12 weeks.
What Was Measured
The subject headings attached to it are Calcium, Hyperparathyroidism, Secondary, Kidney Failure, Chronic, NAD, Niacinamide, Parathyroid Hormone and Phosphorus.
What This Means in Plain Language
This is a clinical trial of NAD+ in people with hyperparathyroidism over 12 weeks.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2004 (Kidney international), a journal based in United States.
More context: the NAD+ compound page, Hyperparathyroidism research.
Our Notes on the Compound
NAD+: The coenzyme that accepts electrons at complex I.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.